ABBV

SEC source: 0001997505-26-000010 · form4-10022026_051005.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 918

Underlying: Common Stock · 59 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001171780-26-000014 · form4-10022026_051002.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,568

Underlying: Common Stock · 129 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001762951-26-000006 · form4-08182026_050811.xml · derivative · entry 3

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,710 shares

Expires 2029-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022.

SEC source: 0001762951-26-000006 · form4-08182026_050811.xml · nonDerivative · entry 2

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,430

SEC source: 0001762951-26-000006 · form4-08182026_050811.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001171780-26-000012 · form4-07022026_050703.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,236

Underlying: Common Stock · 134 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001997505-26-000008 · form4-07022026_050702.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 853

Underlying: Common Stock · 62 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001061632-26-000004 · form4-05122026_050501.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,576

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001171780-26-000010 · form4-05122026_050518.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,964

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2 · balance_after: Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly.

SEC source: 0001222890-26-000003 · form4-05122026_050524.xml · nonDerivative · entry 1

FALK THOMAS J · CIK 0001222890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,321

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001223690-26-000004 · form4-05122026_050522.xml · nonDerivative · entry 1

WADDELL FREDERICK H · CIK 0001223690 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,076

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001239126-26-000002 · form4-05122026_050509.xml · nonDerivative · entry 1

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,869

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001355580-26-000002 · form4-05122026_050520.xml · nonDerivative · entry 1

Roberts Rebecca B · CIK 0001355580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,846

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001466338-26-000003 · form4-05122026_050511.xml · nonDerivative · entry 1

Hart Brett J · CIK 0001466338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,590

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001563579-26-000002 · form4-05122026_050505.xml · nonDerivative · entry 1

BURNSIDE WILLIAM H.L. · CIK 0001563579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,076

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001706126-26-000002 · form4-05122026_050513.xml · nonDerivative · entry 1

MEYER MELODY B · CIK 0001706126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,616

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001916665-26-000002 · form4-05122026_050507.xml · nonDerivative · entry 1

Davis Jennifer L. · CIK 0001916665 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,643

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001997505-26-000006 · form4-05122026_050515.xml · nonDerivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,643

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001171780-26-000006 · form4-04022026_050408.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,865

Underlying: Common Stock · 155 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001448074-26-000007 · form4-04022026_050406.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,369

Underlying: Common Stock · 35 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001997505-26-000004 · form4-04022026_050411.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 784

Underlying: Common Stock · 71 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0002057696-26-000008 · form4-03062026_100340.xml · nonDerivative · entry 1

Purdue David Ryan · CIK 0002057696 · SVP, Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,654

SEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 4

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,619

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,219

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,510

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001563545-26-000004 · form4-03032026_060307.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,794

SEC source: 0001699914-26-000004 · form4-03032026_110308.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,737

SEC source: 0001761675-26-000004 · form4-03032026_060311.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,171

SEC source: 0001762951-26-000004 · form4-03032026_060301.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,430

SEC source: 0001937048-26-000004 · form4-03032026_060305.xml · nonDerivative · entry 1

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,777

SEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,287

SEC source: 0002004979-26-000004 · form4-03032026_110334.xml · nonDerivative · entry 1

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,376

SEC source: 0002057696-26-000004 · form4-03032026_060303.xml · nonDerivative · entry 1

Purdue David Ryan · CIK 0002057696 · SVP, Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,884

SEC source: 0002078592-26-000004 · form4-03062026_100324.xml · nonDerivative · entry 1

Crum Demetris D · CIK 0002078592 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,914

SEC source: 0002057696-26-000010 · form4a-03112026_050317.xml · nonDerivative · entry 1

Purdue David Ryan · CIK 0002057696 · SVP, Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,468

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · derivative · entry 7

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,583

Underlying: Common Stock · 7,292 shares

Expires 2035-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028.

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · derivative · entry 6

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,774

Underlying: Common Stock · 7,775 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027.

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · derivative · entry 5

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,314 shares

Expires 2033-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026.

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 4

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,137

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,451

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001563545-26-000002 · form4-02202026_060209.xml · derivative · entry 7

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,312

Underlying: Common Stock · 20,312 shares

Expires 2036-02-17

F7 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.

SEC source: 0001563545-26-000002 · form4-02202026_060209.xml · nonDerivative · entry 4

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,103

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001563545-26-000002 · form4-02202026_060209.xml · nonDerivative · entry 3

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,465

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001563545-26-000002 · form4-02202026_060209.xml · nonDerivative · entry 2

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,391

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001563545-26-000002 · form4-02202026_060209.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,333

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,251

Underlying: Common Stock · 81,251 shares

Expires 2036-02-17

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,260

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,136

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.